Company news
Tonghua Dongbao Pharmaceutical Co., Ltd. news in 2025
Tonghua Dongbao Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on the Completion of Non-Trade Stock Transfer under the Employee Stock Ownership Plan for R&D and Production System Staff
December 29, 2025
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
December 15, 2025
Announcement on Resolutions of the Employee Representative Meeting
November 28, 2025
Announcement on Obtaining Overseas Drug Registration Certificate for Insulin Aspart Injection
November 12, 2025
Announcement on Initially Repurchasing the Company's Shares through Call Auction
November 6, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
November 3, 2025
Announcement on Results of Share Increase by Controlling Shareholder
October 30, 2025
Announcement on Provision for Asset Impairment and Asset Write-off
October 27, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Subject to No Sales Restrictions Concerning Share Repurchase
October 22, 2025
Announcement on Canceling the Board of Supervisors, Amending the "Articles of Association" and Revising and Adding Some Governance Systems
October 17, 2025
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D
October 15, 2025
Announcement on Obtaining of Overseas Marketing Authorization for Insulin Glargine Injection
October 10, 2025
Announcement on the Completion of Non-Trade Stock Transfer under the 2025 Employee Stock Ownership Plan
October 9, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
September 18, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
September 2, 2025
Announcement on Resolutions of the 16th Meeting of the 11th Board of Directors
August 25, 2025
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in People with T2D
July 25, 2025
Announcement on Expected Increase in Semi-annual Performance for 2025
July 14, 2025
Announcement on SSE’s Reply to Letter of Supervision and Inquiry on Information Disclosure of 2024 Annual Report
July 11, 2025
Announcement on Resignation of Secretary of the Board of Directors
July 4, 2025
Announcement on the Completion of Share Transfer Registration for the Negotiated Transfer of Partial Shares of Xiamen Amoytop Biotech Co., Ltd.
July 3, 2025
Announcement on Completion of Stock Sales under the 2020 Employee Stock Ownership Plan
June 27, 2025
Indicative Announcement on Equity Change of Controlling Shareholder and Its Persons Acting in Concert Reaching 1%
June 18, 2025
Announcement on Implementation of Dividend Distribution for 2024
June 17, 2025
Announcement on Resolution of the 1st Extraordinary General Meeting in 2025
June 9, 2025
Announcement on Resolution of the 15th Meeting of the 11th Board of Directors
May 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 21, 2025
Announcement on Change of Information Regarding the 2024 Annual and Q1 2025 Performance Briefing
May 19, 2025
Announcement on Obtaining Overseas Drug Registration Certificate for Isophane Protamine Human Insulin Injection
May 13, 2025
Announcement on Amending Some Clauses of the Articles of Association
April 29, 2025